[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
A patient with a 5 year history of slow-progressive Lambert-Eaton Myasthenic Syndrome (LEMS) was treated for a period of 12 months with 3,4-diaminopyridine (3,4-DAP). The therapy led to an objective increase in muscle power. During the treatment period, there was no increase in muscle weakness, but attempts at withdrawal of the drug confirmed a progression. The mouth dryness disappeared and autonomic regulation disturbances were improved. All of the laboratory parameters remained unchanged. A neoplasia was excluded by extensive endoscopic and radiological investigations. Side-effects included initial perioral paresthesia and, later, paresthesia down the skin and along the ulnar edge of the forearm. 3,4-DAP seems to be an effective and acceptable long-term symptomatic therapy in LEMS.
Jost
W H
WH
Neurologische Klinik der Universität des Saarlandes, Homburg/Saar, R.F.A.
Mielke
U
U
Forrett-Kaminsky
M C
MC
Schimrigk
K
K
D015761:4-Aminopyridine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077770:Amifampridine; D004576:Electromyography; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced
D015761:4-Aminopyridine; D000077770:Amifampridine
Traitement au long cours du syndrome de Lambert-Eaton par la 3,4 diaminopyridine.